|Biologic disease-modifying antirheumatic drugs|Tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol); other biologic response modifiers (abatacept, tocilizumab, anakinra, canakinumab)|
|Glucocorticoids|Oral (any); intravenous (any); intraarticular (triamcinolone acetonide, triamcinolone hexacetonide)|</p>